Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-9546
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates ; volume:5 ; number:1 ; day:21 ; month:6 ; year:2008 ; pages:21-29 ; date:3.2009
Purinergic signalling ; 5, Heft 1 (21.6.2008), 21-29, 3.2009
- Creator
-
Kalla, Rao V.
Zablocki, Jeff
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11302-008-9119-x
- URN
-
urn:nbn:de:101:1-2021082021173454872414
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kalla, Rao V.
- Zablocki, Jeff
- SpringerLink (Online service)
Other Objects (12)
Irreversible Antagonists for the Adenosine A2B Receptor
Barbiturates are selective antagonists at A1 adenosine receptors
Pharmacological characterisation of novel adenosine A3 receptor antagonists
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes
A2A adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
Automating the discovery of linking candidates
Discovery of protein-stabilizing excipient candidates
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure–activity profile
PPB-Affinity: Protein-Protein Binding Affinity dataset for AI-based protein drug discovery
Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile
Rapid discovery of high-affinity antibodies via massively parallel sequencing, ribosome display and affinity screening
Irreversible Antagonists for the Adenosine A2B Receptor
Barbiturates are selective antagonists at A1 adenosine receptors
Pharmacological characterisation of novel adenosine A3 receptor antagonists
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes
A2A adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
Automating the discovery of linking candidates
Discovery of protein-stabilizing excipient candidates
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure–activity profile
PPB-Affinity: Protein-Protein Binding Affinity dataset for AI-based protein drug discovery
Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile
Rapid discovery of high-affinity antibodies via massively parallel sequencing, ribosome display and affinity screening
Irreversible Antagonists for the Adenosine A2B Receptor
Barbiturates are selective antagonists at A1 adenosine receptors
Pharmacological characterisation of novel adenosine A3 receptor antagonists
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes
A2A adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
Automating the discovery of linking candidates
Discovery of protein-stabilizing excipient candidates
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure–activity profile
PPB-Affinity: Protein-Protein Binding Affinity dataset for AI-based protein drug discovery
Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile